On-line formation, separation, and estrogen receptor affinity screening of cytochrome P450-derived metabolites of selective estrogen receptor modulators

Drug Metabolism and Disposition

Volumn 34, Issue 9, 2006, Pages 1640-1649

  Van Liempd, S M ^a   Kool, J ^a   Niessen, W M A ^a   Van Elswijk, D E ^b   Irth, H ^a,b   Vermeulen, N P E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Kiadis BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BIOREACTOR; BIOTRANSFORMATION; CHROMATOGRAPHY; CONTROLLED STUDY; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SCREENING; SWINE;

ANIMALS; AUTOMATION; BIOREACTORS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ESTROGEN RECEPTOR ALPHA; KINETICS; LIVER; MASS SPECTROMETRY; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RALOXIFENE; RATS; REPRODUCIBILITY OF RESULTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SWINE; TAMOXIFEN;

SUS SCROFA;

EID: 33747817662     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010355     Document Type: Article

References (32)

1. Ali S and Coombes RC (2000) Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mamm Gland Biol Neoplasia 5:271-281.
2. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, et al. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914.
3. Crewe HK, Notley LM, Wunsch RM, Lennard MS, and Gillam EM (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874.
4. Desta Z, Ward BA, Soukhova NV, and Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075.
5. Eiler S, Gangloff M, Duclaud S, Moras D, and Ruff M (2001) Overexpression, purification, and crystal structure of native ER alpha LBD. Protein Expr Purif 22:165-173.
6. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science (Wash DC) 286:487-491.
7. Fan PW and Bolton JL (2001) Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab Dispos 29:891-896.
8. Fura A (2006) Role of pharmacologically active metabolites in drug discovery and development. Drug Discov Today 11:133-142.
9. Gokhale MS, Bunton TE, Zurlo J, and Yager JD (1997) Cytochrome P450 isoenzyme activities in cultured rat and mouse liver slices. Xenobiotica 27:341-355.
10. Ingelman-Sundberg M and Rodriguez-Antona C (2005) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 360:1563-1570.
11. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, and Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.
12. Kool J, Ramautar R, van Liempd SM, Beckman J, de Kanter FJ, Meerman JH, Schenk T, Irth H, Commandeur JN, and Vermeulen NP (2006) Rapid on-line profiling of estrogen receptor binding metabolites of tamoxifen. J Med Chem 49:3287-3292.
13. Kool J, van Liempd SM, Ramautar R, Schenk T, Meerman JH, Irth H, Commandeur JN, and Vermeulen NP (2005) Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography. J Biomol Screen 10:427-436.
14. Lim HK, Stellingweif S, Sisenwine S, and Chan KW (1999) Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. J Chromatogr A 831:227-241.
15. Mani C, Hodgson E, and Kupfer D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab Dispos 21:657-661.
16. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, and Cummings SR (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761.
17. Mayol RF, Cole CA, Luke GM, Colson KL, and Kerns EH (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 22:304-311.
18. Morello KC, Wurz GT, and DeGregorio MW (2002) SERMs: current status and future trends. Crit Rev Oncol Hematol 43:63-76.
19. Notley LM, De Wolf CJ, Wunsch RM, Lancaster RG, and Gillam EM (2002) Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes. Chem Res Toxicol 15:614-622.
20. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
21. Oosterkamp AJ, Villaverde Herraiz MT, Irth H, Tjaden UR, and van der Greef J (1996) Reversed-phase liquid chromatography coupled on-line to receptor affinity detection based on the human estrogen receptor. Anal Chem 68:1201-1206.
22. O'Regan RM and Jordan VC (2002) The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3:207-214.
23. Roy U, Joshua R, Stark RL, and Balazy M (2005) Cytochrome P450/NADPH-dependent biosynthesis of 5,6-trans-epoxyeicosatrienoic acid from 5,6-trans-arachidonic acid. Biochem J 390:719-727.
24. Schenk T, Breel GJ, Koevoets P, van den Berg S, Hogenboom AC, Irth H, Tjaden UR, and van der Greef J (2003) Screening of natural products extracts for the presence of phosphodiesterase inhibitors using liquid chromatography coupled online to parallel biochemical detection and chemical characterization. J Biomol Screen 8:421-429.
25. Schobel U, Frenay M, van Elswijk DA, McAndrews JM, Long KR, Olson LM, Bobzin SC, and Irth H (2001) High resolution screening of plant natural product extracts for estrogen receptor alpha and beta binding activity using an online HPLC-MS biochemical detection system. J Biomol Screen 6:291-303.
26. Sharma M, Shubert DE, Lewis J, McGarrigle BP, Bofinger DP, and Olson JR (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem-Biol Interact 146:237-249.
27. Spelsberg TC, Subramaniam M, Riggs BL, and Khosla S (1999) The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13:819-828.
28. van Liempd SM, Kool J, Reinen J, Schenk T, Meerman JH, Irth H, and Vermeulen NP (2005) Development and validation of a microsomal online cytochrome P450 bioreactor coupled to solid-phase extraction and reversed-phase liquid chromatography. J Chromatogr A 1075:205-212.
29. Yamazaki H, Inoue K, Turvy CG, Guengerich FP, and Shimada T (1997) Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 25:168-174.
30. Yenes S, Commandeur JN, Vermeulen NP, and Messeguer A (2004) In vitro biotransformation of 3,4-dihydro-6-hydroxy-2,2-dimethyl-7-methoxy-1(2H)- benzopyran (CR-6), a potent lipid peroxidation inhibitor and nitric oxide scavenger, in rat liver microsomes. Chem Res Toxicol 17:904-913.
31. Yu L, Liu H, Li W, Zhang F, Luckie C, van Breemen RB, Thatcher GR, and Bolton JL (2004) Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem Res Toxicol 17:879-888.
32. Zuber R, Anzenbacherova E, and Anzenbacher P (2002) Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189-198.